We evaluated zolbetuximab in combination with ZA and IL-2 in patients with advanced or metastatic G/GEJ adenocarcinoma to determine activation and kinetic profiles of immune cell populations induced by ZA with or without IL-2. The gene discussed is IL2; the disease is gastroesophageal junction adenocarcinoma.